At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 82 enrolled
Drug / intervention
Etanercept (Enbrel) +1 moredrug
Likely dose
Etanercept (Enbrel) 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicentre, Double-Blind, Placebo-Controlled, Randomised Study of Etanercept in the Treatment of Adult Patients With Active, Severe, and Advanced Axial Ankylosing Spondylitis
Wyeth is now a wholly owned subsidiary of Pfizer·interventional·Posted Jan 11, 2007·Updated Jun 29, 2010
In Brief
A Phase 4 clinical trial evaluating Etanercept (Enbrel) and Placebo for Ankylosing Spondylitis. Completed, enrolled 82 participants across 21 sites in 4 countries.
Detailed Summary
Evaluation of the efficacy and safety of etanercept (Enbrel) in patients with active, severe and advanced ankylosing spondylitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnkylosing Spondylitis
CountriesFrance, Germany, Hungary, Netherlands
Collaborators--
Timeline
Phase 4CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2007
First PostedJan 2007
Primary CompletionFeb 2009
Study CompletionMay 2009
TodayJul 2026
First PostedJan 11, 2007
Enrollment StartJan 1, 2007
Primary CompletionFeb 1, 2009
Study CompletionMay 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 19.5 years ago
Interventions
Etanercept (Enbrel)drug
50 mg injection once weekly
Placeboother
placebo